United States Market for Ankylosing Spondylitis Pharmacotherapy

Additional Information

Report Excerpt

The market for ankylosing spondylitis (AS) add-on pharmacotherapeutics currently comprises a single class: tumor necrosis factor (TNF) inhibitors. Availability of alternative therapies for TNF inhibitor refractory patients with moderate to severe disease represents a significant unmet need.

Revenue generated from sales of TNF inhibitors for AS in the United States was approximately $ million in 2011 and was dominated by Abbott. Revenue for the AS therapeutic area is expected to increase to approximately $ million in 2017.

Novel therapies aimed at alternative targets such as interleukin-17 (IL-17), interleukin 12/23 (IL-12/23), phosphodiesterase type 4 (PDE4), and janus kinase (JAK) are in active development, with an anti-IL-17 closest to approval for AS.

Development of therapies for this complex disease is hindered by several factors, including incompletely understood pathogenesis of AS and a low level of disease awareness.

Estimates of the prevalence of AS vary widely, but it occurs in approximately percent of the adult population. It usually presents in young adults, with a higher prevalence in males versus females.

While many patients will respond well to non-steroidal anti-inflammatory drugs (NSAIDs), approximately .... percent (just under 200,000 in the United States in 2011) do not and are candidates for add-on therapy such as biologics.

Diagnosis and initiation of appropriate treatment is often delayed by up to ten years due to unawareness of the disease.